Big Tobacco Drives Nicotine Pouches as Cigarette Sales Decline

Nicotine pouches have quickly become one of Big Tobacco’s most significant bets on a future beyond traditional cigarettes, offering rapid growth, attractive profit margins, and lighter regulation than many rival alternatives, Reuters reports. Major tobacco investors are closely monitoring whether popular brands like Philip Morris International’s Zyn and British American Tobacco’s Velo can achieve broader acceptance outside of Scandinavia and the United States, where oral nicotine products are already commonplace, to serve as a new profit engine as cigarette sales decline.

Fast-Growing Nicotine Pouches Emerge as Big Tobacco’s Profit Engine

Pouches are small packets placed under the lip that contain no tobacco leaf, instead delivering nicotine through absorption via the oral mucosa. Because they produce no smoke or vapor, users can consume them in locations where smoking is restricted. British American Tobacco Chief Executive Tadeu Marroco noted in an interview that this is an engine of growth … that has the potential to replace cigarettes in the long run, describing the items as cheaper and easier to use than many smoking alternatives.

Financial Performance and Market Projections

Driven by high growth rates and profit margins that surpass both e-cigarettes and heated tobacco products, tobacco giants are doubling down on the category. British American Tobacco predicts that industry-wide pouch revenue will surge from £4 billion in 2025 to reach £11 billion (approximately $15 billion) by 2030, ultimately overtaking vapes. The company also projects that global pouch users will reach 47 million by that year, representing slightly more than half the number of vape users.

Big Tobacco Drives Nicotine Pouches as Cigarette Sales Decline — Photo: AOL

Data highlights the exceptional earning power of the category. Philip Morris International reported that its U.S. nicotine pouch business generated gross profit per 1,000 units in 2024 that was eight times higher than its overseas cigarette operations. By comparison, its flagship heated tobacco device, IQOS, generated only 2.4 times the gross profit per thousand units of the international cigarette benchmark. Jefferies analyst Andrei Andon-Ionita noted that tobacco company valuations are increasingly linked to pouch performance.

Despite these high margins, cigarettes remain the center of industry profits. At Philip Morris, oral nicotine products account for a mere 2.6% of total sales volume. When the company reported second-quarter results that surpassed market expectations, Bernstein analysts pointed out that investor focus on Zyn had obscured the continued dominance of its traditional cigarette business, which recently saw an unexpected increase in sales.

Regulatory Pressures and Global Hurdles

The rapidly expanding category faces substantial hurdles, notably sustaining growth as regulators grow increasingly concerned about youth uptake and marketing practices. According to the Centers for Disease Control and Prevention, nicotine is a highly addictive chemical that is especially dangerous for youth, young adults, and pregnant women. The World Health Organization attributes the expansion of pouch use to aggressive marketing—including sports and music event sponsorships and free sample distribution—alongside high-nicotine products, prompting calls for stricter oversight.

Packages of Velo, Fre, Alp and Zyn nicotine pouches in a photo illustration in New York City, U.S., March 27, 2026 — Photo: Reuters

While the World Health Organization reported that 160 countries lacked specific regulations governing nicotine pouches as of May 2026, the regulatory landscape is shifting. France has banned nicotine pouches outright, Finland has implemented regulations including plain packaging requirements, and both the United Kingdom and the European Union are moving toward tighter controls.

Beyond regulatory hurdles, market expansion faces cultural barriers. According to Andrei Andon-Ionita, outside of regions like the Nordic countries, the lack of an established oral nicotine culture remains the single biggest obstacle to broader consumer adoption, as shoppers in many countries are far more comfortable inhaling nicotine than consuming it orally.